In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Vericel trades at $42.97, significantly above the PERT-weighted fair value of $19.36, reflecting a 55% downside risk per valuation models. Despite high liquidity, low profitability and growth scores suggest operational challenges. Monte Carlo analysis shows minimal price downside below current levels, indicating price stability amid potential overvaluation.